1
|
Mariotto E, Corallo D, Pantile M, Giarin E, Pigazzi M, Basso G, Viola G, Aveic S. BAG1 down-regulation increases chemo-sensitivity of acute lymphoblastic leukaemia cells. J Cell Mol Med 2021; 25:9060-9065. [PMID: 34402163 PMCID: PMC8435410 DOI: 10.1111/jcmm.16822] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Revised: 07/12/2021] [Accepted: 07/16/2021] [Indexed: 12/13/2022] Open
Abstract
BCL2‐associated athanogene‐1 (BAG1) is a multi‐functional protein that is found deregulated in several solid cancers and in paediatric acute myeloid leukaemia. The investigation of BAG1 isoforms expression and intracellular localization in B‐cell acute lymphoblastic leukaemia (B‐ALL) patient‐derived specimens revealed that BAG1 levels decrease during disease remission, compared to diagnosis, but drastically increase at relapse. In particular, at diagnosis both BAG1‐L and BAG1‐M isoforms are mainly nuclear, while during remission the localization pattern changes, having BAG1‐M almost exclusively in the cytosol indicating its potential cytoprotective role in B‐ALL. In addition, knockdown of BAG1/BAG3 induces cell apoptosis and G1‐phase cell cycle arrest and, more intriguingly, shapes cell response to chemotherapy. BAG1‐depleted cells show an increased sensitivity to the common chemotherapeutic agents, dexamethasone or daunorubicin, and to the BCL2 inhibitor ABT‐737. Moreover, the BAG1 inhibitor Thio‐2 induces a cytotoxic effect on RS4;11 cells both in vitro and in a zebrafish xenograft model and strongly synergizes with pan‐BCL inhibitors. Collectively, these data sustain BAG1 deregulation as a critical event in assuring survival advantage to B‐ALL cells.
Collapse
Affiliation(s)
- Elena Mariotto
- Department of Woman's and Child's Health, Haematology-Oncology Clinic and Lab, University of Padova, Padova, Italy
| | - Diana Corallo
- Neuroblastoma Laboratory, Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy
| | - Marcella Pantile
- Neuroblastoma Laboratory, Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy
| | - Emanuela Giarin
- Department of Woman's and Child's Health, Haematology-Oncology Clinic and Lab, University of Padova, Padova, Italy
| | - Martina Pigazzi
- Department of Woman's and Child's Health, Haematology-Oncology Clinic and Lab, University of Padova, Padova, Italy.,Pediatric hematology, oncology and hematopoietic cell&gene therapy, Fondazione Istituto di Ricerca Pediatrica - Città della Speranza, Padova, Italy
| | - Giuseppe Basso
- Department of Woman's and Child's Health, Haematology-Oncology Clinic and Lab, University of Padova, Padova, Italy
| | - Giampietro Viola
- Department of Woman's and Child's Health, Haematology-Oncology Clinic and Lab, University of Padova, Padova, Italy.,Pediatric hematology, oncology and hematopoietic cell&gene therapy, Fondazione Istituto di Ricerca Pediatrica - Città della Speranza, Padova, Italy
| | - Sanja Aveic
- Neuroblastoma Laboratory, Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy.,Department of Dental Materials and Biomaterials Research, RWTH Aachen University Hospital, Aachen, Germany
| |
Collapse
|
2
|
Popov A, Buldini B, De Lorenzo P, Disarò S, Verzhbitskaya T, Movchan L, Giarin E, Shorikov E, Di Meglio A, Tsaur G, Parasole R, Miakova N, Boichenko E, Kondratchik K, Aleinikova O, Karachunskiy A, Roumiantsev A, Locatelli F, Biondi A, Pieters R, Valsecchi MG, Fechina L, Basso G. Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols. Leukemia 2020; 34:3042-3046. [PMID: 32533093 DOI: 10.1038/s41375-020-0912-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2019] [Revised: 06/03/2020] [Accepted: 06/04/2020] [Indexed: 12/22/2022]
Affiliation(s)
- Alexander Popov
- National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
| | - Barbara Buldini
- Dipartimento di Salute della Donna e del Bambino, University of Padua, Padua, Italy
| | - Paola De Lorenzo
- Interfant Trial Data Center, School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.,Tettamanti Research Center, Pediatric Clinic, University of Milan-Bicocca, Fondazione MBBM/ S. Gerardo Hospital Monza, Monza, Italy
| | - Silvia Disarò
- Fondazione Città della Speranza - Onlus, Dipartimento di Salute della Donna e del Bambino, University of Padova, Padova, Italy
| | - Tatiana Verzhbitskaya
- Regional Children Hospital, Ekaterinburg, Russian Federation.,Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation
| | - Liudmila Movchan
- Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus
| | - Emanuela Giarin
- Fondazione Città della Speranza - Onlus, Dipartimento di Salute della Donna e del Bambino, University of Padova, Padova, Italy
| | - Egor Shorikov
- PET-Technology Center of Nuclear Medicine, Ekaterinburg, Russian Federation
| | - Annamaria Di Meglio
- Fondazione Città della Speranza - Onlus, Dipartimento di Salute della Donna e del Bambino, University of Padova, Padova, Italy
| | - Grigory Tsaur
- Regional Children Hospital, Ekaterinburg, Russian Federation.,Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation
| | - Rosanna Parasole
- Department of Pediatric Hemato-Oncology, Santobono-Pausilipon Hospital, Naples, Italy
| | - Natalia Miakova
- National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
| | - Elmira Boichenko
- City Children's Hospital №1, Saint-Petersburg, Russian Federation
| | | | - Olga Aleinikova
- Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus
| | - Alexander Karachunskiy
- National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
| | - Alexander Roumiantsev
- National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
| | - Franco Locatelli
- Department of Pediatric Hematology and Oncology, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.,Sapienza, University of Rome, Rome, Italy
| | - Andrea Biondi
- Tettamanti Research Center, Pediatric Clinic, University of Milan-Bicocca, Fondazione MBBM/ S. Gerardo Hospital Monza, Monza, Italy
| | - Rob Pieters
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
| | - Maria Grazia Valsecchi
- Interfant Trial Data Center, School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy
| | - Larisa Fechina
- Regional Children Hospital, Ekaterinburg, Russian Federation.,Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation
| | - Giuseppe Basso
- Dipartimento di Salute della Donna e del Bambino, University of Padua, Padua, Italy.,Italian Institute for Genomic Medicine, Turin, Italy
| |
Collapse
|
3
|
Vendramini E, Giordan M, Giarin E, Michielotto B, Fazio G, Cazzaniga G, Biondi A, Silvestri D, Valsecchi MG, Muckenthaler MU, Kulozik AE, Gattei V, Izraeli S, Basso G, Te Kronnie G. High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia. Oncotarget 2018; 8:42398-42413. [PMID: 28415578 PMCID: PMC5522075 DOI: 10.18632/oncotarget.16392] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Accepted: 03/04/2017] [Indexed: 12/19/2022] Open
Abstract
ERG-related leukemia is a B cell precursor acute lymphoblastic leukemia (BCP ALL) subtype characterized by aberrant expression of DUX4 and ERG transcription factors, and highly recurrent ERG intragenic deletions. ERG-related patients have remarkably favorable outcome despite a high incidence of inauspicious IKZF1 aberrations. We describe clinical and genomic features of the ERG-related cases in an unselected cohort of B-other BCP ALL pediatric patients enrolled in the AIEOP ALL 2000 therapeutic protocol. We report a small noncoding RNA signature specific of ERG-related group, with up-regulation of miR-125b-2 cluster on chromosome 21 and several snoRNAs in the Prader-Willi locus at 15q11.2, including the orphan SNORD116 cluster.
Collapse
Affiliation(s)
- Elena Vendramini
- Department of Women's and Children's Health, University of Padova, Padova, Italy.,Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.,Tel Aviv University, Tel Aviv, Israel
| | - Marco Giordan
- Department of Women's and Children's Health, University of Padova, Padova, Italy
| | - Emanuela Giarin
- Department of Women's and Children's Health, University of Padova, Padova, Italy
| | - Barbara Michielotto
- Department of Women's and Children's Health, University of Padova, Padova, Italy
| | - Grazia Fazio
- Centro Ricerca Tettamanti, Clinica Pediatrica, University of Milano-Bicocca, Monza, Italy
| | - Gianni Cazzaniga
- Centro Ricerca Tettamanti, Clinica Pediatrica, University of Milano-Bicocca, Monza, Italy
| | - Andrea Biondi
- Centro Ricerca Tettamanti, Clinica Pediatrica, University of Milano-Bicocca, Monza, Italy
| | - Daniela Silvestri
- Centro Ricerca Tettamanti, Clinica Pediatrica, University of Milano-Bicocca, Monza, Italy
| | | | - Martina U Muckenthaler
- Department of Pediatric Oncology Hematology, University of Heidelberg, Heidelberg, Germany
| | - Andreas E Kulozik
- Department of Pediatric Oncology Hematology, University of Heidelberg, Heidelberg, Germany
| | - Valter Gattei
- Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano (PN), Italy
| | - Shai Izraeli
- Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.,Tel Aviv University, Tel Aviv, Israel
| | - Giuseppe Basso
- Department of Women's and Children's Health, University of Padova, Padova, Italy
| | - Geertruy Te Kronnie
- Department of Women's and Children's Health, University of Padova, Padova, Italy
| |
Collapse
|
4
|
Lovisa F, Zecca M, Rossi B, Campeggio M, Magrin E, Giarin E, Buldini B, Songia S, Cazzaniga G, Mina T, Acquafredda G, Quarello P, Locatelli F, Fagioli F, Basso G. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. Br J Haematol 2018; 180:680-693. [DOI: 10.1111/bjh.15086] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2017] [Accepted: 11/07/2017] [Indexed: 01/20/2023]
Affiliation(s)
- Federica Lovisa
- Clinic of Paediatric Haemato-Oncology, Department of Women's and Children's Health; University of Padua; Padua Italy
- Istituto di Ricerca Pediatrica Città della Speranza; Padua Italy
| | - Marco Zecca
- Paediatric Haematology/Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - Bartolomeo Rossi
- Clinic of Paediatric Haemato-Oncology, Department of Women's and Children's Health; University of Padua; Padua Italy
- Istituto di Ricerca Pediatrica Città della Speranza; Padua Italy
| | - Mimma Campeggio
- Clinic of Paediatric Haemato-Oncology, Department of Women's and Children's Health; University of Padua; Padua Italy
- Istituto di Ricerca Pediatrica Città della Speranza; Padua Italy
| | - Elisa Magrin
- Clinic of Paediatric Haemato-Oncology, Department of Women's and Children's Health; University of Padua; Padua Italy
- Istituto di Ricerca Pediatrica Città della Speranza; Padua Italy
- Departments of Biotherapy; Necker Children's Hospital; Assistance Publique-Hôpitaux de Paris; Paris France
| | - Emanuela Giarin
- Clinic of Paediatric Haemato-Oncology, Department of Women's and Children's Health; University of Padua; Padua Italy
- Istituto di Ricerca Pediatrica Città della Speranza; Padua Italy
| | - Barbara Buldini
- Clinic of Paediatric Haemato-Oncology, Department of Women's and Children's Health; University of Padua; Padua Italy
| | - Simona Songia
- Centro Ricerca Tettamanti; Paediatric Clinics; University of Milano-Bicocca; San Gerardo Hospital/Fondazione MBBM; Monza Italy
| | - Giovanni Cazzaniga
- Centro Ricerca Tettamanti; Paediatric Clinics; University of Milano-Bicocca; San Gerardo Hospital/Fondazione MBBM; Monza Italy
| | - Tommaso Mina
- Paediatric Haematology/Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - Gloria Acquafredda
- Paediatric Haematology/Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - Paola Quarello
- Paediatric Onco-Haematology; Stem Cell Transplantation and Cellular Therapy Division; Regina Margherita Children's Hospital; Turin Italy
| | - Franco Locatelli
- Paediatric Haematology/Oncology; IRCCS Ospedale “Bambino Gesù”; Roma Italy
- Department of Paediatric Sciences; University of Pavia; Pavia Italy
| | - Franca Fagioli
- Paediatric Onco-Haematology; Stem Cell Transplantation and Cellular Therapy Division; Regina Margherita Children's Hospital; Turin Italy
| | - Giuseppe Basso
- Clinic of Paediatric Haemato-Oncology, Department of Women's and Children's Health; University of Padua; Padua Italy
- Istituto di Ricerca Pediatrica Città della Speranza; Padua Italy
| |
Collapse
|
5
|
Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salomé B, Lecciso M, Salvestrini V, Verdeil G, Racle J, Papayannidis C, Morita H, Pizzitola I, Grandclément C, Bohner P, Bruni E, Girotra M, Pallavi R, Falvo P, Leibundgut EO, Baerlocher GM, Carlo-Stella C, Taurino D, Santoro A, Spinelli O, Rambaldi A, Giarin E, Basso G, Tresoldi C, Ciceri F, Gfeller D, Akdis CA, Mazzarella L, Minucci S, Pelicci PG, Marcenaro E, McKenzie ANJ, Vanhecke D, Coukos G, Mavilio D, Curti A, Derré L, Jandus C. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun 2017; 8:593. [PMID: 28928446 PMCID: PMC5605498 DOI: 10.1038/s41467-017-00678-2] [Citation(s) in RCA: 163] [Impact Index Per Article: 23.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2017] [Accepted: 07/19/2017] [Indexed: 01/29/2023] Open
Abstract
Group 2 innate lymphoid cells (ILC2s) are involved in human diseases, such as allergy, atopic dermatitis and nasal polyposis, but their function in human cancer remains unclear. Here we show that, in acute promyelocytic leukaemia (APL), ILC2s are increased and hyper-activated through the interaction of CRTH2 and NKp30 with elevated tumour-derived PGD2 and B7H6, respectively. ILC2s, in turn, activate monocytic myeloid-derived suppressor cells (M-MDSCs) via IL-13 secretion. Upon treating APL with all-trans retinoic acid and achieving complete remission, the levels of PGD2, NKp30, ILC2s, IL-13 and M-MDSCs are restored. Similarly, disruption of this tumour immunosuppressive axis by specifically blocking PGD2, IL-13 and NKp30 partially restores ILC2 and M-MDSC levels and results in increased survival. Thus, using APL as a model, we uncover a tolerogenic pathway that may represent a relevant immunosuppressive, therapeutic targetable, mechanism operating in various human tumour types, as supported by our observations in prostate cancer.Group 2 innate lymphoid cells (ILC2s) modulate inflammatory and allergic responses, but their function in cancer immunity is still unclear. Here the authors show that, in acute promyelocytic leukaemia, tumour-activated ILC2s secrete IL-13 to induce myeloid-derived suppressor cells and support tumour growth.
Collapse
Affiliation(s)
- Sara Trabanelli
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Biopole 3-02DB61, Ch. Des Boveresses 155, CH-1066, Epalinges, Switzerland.
| | - Mathieu F Chevalier
- Urology Research Unit, Lausanne University Hospital (CHUV), 1011, Lausanne, Switzerland
| | - Amaia Martinez-Usatorre
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Biopole 3-02DB61, Ch. Des Boveresses 155, CH-1066, Epalinges, Switzerland
| | - Alejandra Gomez-Cadena
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Biopole 3-02DB61, Ch. Des Boveresses 155, CH-1066, Epalinges, Switzerland
| | - Bérengère Salomé
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Biopole 3-02DB61, Ch. Des Boveresses 155, CH-1066, Epalinges, Switzerland
| | - Mariangela Lecciso
- Department of Specialistic, Diagnostic and Experimental Medicine, Institute of Hematology "Seràgnoli", University of Bologna, 40138, Bologna, Italy
| | - Valentina Salvestrini
- Department of Specialistic, Diagnostic and Experimental Medicine, Institute of Hematology "Seràgnoli", University of Bologna, 40138, Bologna, Italy
| | - Grégory Verdeil
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Biopole 3-02DB61, Ch. Des Boveresses 155, CH-1066, Epalinges, Switzerland
| | - Julien Racle
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Biopole 3-02DB61, Ch. Des Boveresses 155, CH-1066, Epalinges, Switzerland.,Swiss Institute of Bioinformatics (SIB), 1015, Lausanne, Switzerland
| | - Cristina Papayannidis
- Department of Specialistic, Diagnostic and Experimental Medicine, Institute of Hematology "Seràgnoli", University of Bologna, 40138, Bologna, Italy
| | - Hideaki Morita
- Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 7270, Davos, Switzerland.,Christine Kühne-Center for Allergy Research and Education, 7265, Davos, Switzerland
| | - Irene Pizzitola
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Biopole 3-02DB61, Ch. Des Boveresses 155, CH-1066, Epalinges, Switzerland
| | - Camille Grandclément
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Biopole 3-02DB61, Ch. Des Boveresses 155, CH-1066, Epalinges, Switzerland
| | - Perrine Bohner
- Urology Research Unit, Lausanne University Hospital (CHUV), 1011, Lausanne, Switzerland
| | - Elena Bruni
- Department of Medical Biotechnologies and Translational Medicine, University of Milan, 20133, Milan, Italy.,Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, 20089, Rozzano-Milan, Italy
| | - Mukul Girotra
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Biopole 3-02DB61, Ch. Des Boveresses 155, CH-1066, Epalinges, Switzerland
| | - Rani Pallavi
- Department of Experimental Oncology, European Institute of Oncology, 20139, Milan, Italy
| | - Paolo Falvo
- Department of Experimental Oncology, European Institute of Oncology, 20139, Milan, Italy
| | | | - Gabriela M Baerlocher
- Department of Hematology, Bern University Hospital, University of Bern, 3010, Bern, Switzerland
| | - Carmelo Carlo-Stella
- Humanitas Cancer Center, Humanitas Clinical and Research Center, 20089, Rozzano-Milan, Italy.,Department of Biomedical Sciences, Humanitas University, 20089, Rozzano-Milan, Italy
| | - Daniela Taurino
- Humanitas Cancer Center, Humanitas Clinical and Research Center, 20089, Rozzano-Milan, Italy.,Department of Biomedical Sciences, Humanitas University, 20089, Rozzano-Milan, Italy
| | - Armando Santoro
- Humanitas Cancer Center, Humanitas Clinical and Research Center, 20089, Rozzano-Milan, Italy.,Department of Biomedical Sciences, Humanitas University, 20089, Rozzano-Milan, Italy
| | - Orietta Spinelli
- Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, 24127, Bergamo, Italy
| | - Alessandro Rambaldi
- Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, 24127, Bergamo, Italy.,Università Statale di Milano, 20122, Milan, Italy
| | - Emanuela Giarin
- Dipartimento per la Salute della Donna e del Bambino, Clinica di Oncoematologia Pediatrica, University of Padova, 35128, Padova, Italy
| | - Giuseppe Basso
- Dipartimento per la Salute della Donna e del Bambino, Clinica di Oncoematologia Pediatrica, University of Padova, 35128, Padova, Italy
| | - Cristina Tresoldi
- Immunoematologia e Medicina Trasfusionale, Laboratorio Ematologia Molecolare, Biobanca Neoplasie Ematologiche, San Raffaele Hospital, 20132, Milano, Italy
| | - Fabio Ciceri
- Divisione di Ricerca di Medicina Rigenerativa, Terapia Cellulare e Genica IRCCS, San Raffaele Hospital, 20132, Milano, Italy
| | - David Gfeller
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Biopole 3-02DB61, Ch. Des Boveresses 155, CH-1066, Epalinges, Switzerland.,Swiss Institute of Bioinformatics (SIB), 1015, Lausanne, Switzerland
| | - Cezmi A Akdis
- Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 7270, Davos, Switzerland
| | - Luca Mazzarella
- Department of Experimental Oncology, European Institute of Oncology, 20139, Milan, Italy.,Division of Innovative Therapies, European Institute of Oncology, 20141, Milan, Italy
| | - Saverio Minucci
- Department of Experimental Oncology, European Institute of Oncology, 20139, Milan, Italy
| | - Pier Giuseppe Pelicci
- Department of Experimental Oncology, European Institute of Oncology, 20139, Milan, Italy
| | - Emanuela Marcenaro
- Department of Experimental Medicine (DI.ME.S.)-Section of Histology, and Center of Excellent of Biomedical Research (CEBR), University of Genoa, 16132, Genoa, Italy
| | | | - Dominique Vanhecke
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Biopole 3-02DB61, Ch. Des Boveresses 155, CH-1066, Epalinges, Switzerland
| | - George Coukos
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Biopole 3-02DB61, Ch. Des Boveresses 155, CH-1066, Epalinges, Switzerland
| | - Domenico Mavilio
- Department of Medical Biotechnologies and Translational Medicine, University of Milan, 20133, Milan, Italy.,Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, 20089, Rozzano-Milan, Italy
| | - Antonio Curti
- Department of Specialistic, Diagnostic and Experimental Medicine, Institute of Hematology "Seràgnoli", University of Bologna, 40138, Bologna, Italy
| | - Laurent Derré
- Urology Research Unit, Lausanne University Hospital (CHUV), 1011, Lausanne, Switzerland
| | - Camilla Jandus
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Biopole 3-02DB61, Ch. Des Boveresses 155, CH-1066, Epalinges, Switzerland.
| |
Collapse
|
6
|
Franca R, Rebora P, Basso G, Biondi A, Cazzaniga G, Crovella S, Decorti G, Fagioli F, Giarin E, Locatelli F, Poggi V, Valsecchi MG, Rabusin M. Glutathione S-transferase homozygous deletions and relapse in childhood acute lymphoblastic leukemia: a novel study design in a large Italian AIEOP cohort. Pharmacogenomics 2012; 13:1905-16. [DOI: 10.2217/pgs.12.169] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
Aim: In the AIEOP-BFM 2000 trial, 15% of pediatric patients treated according to risk-adapted polychemotherapeutic regimens relapsed. The present study aimed to investigate the influence of GST-M1 and GST-T1 deletions on clinical outcome of children with acute lymphoblastic leukemia treated according to the AIEOP-BFM ALL 2000 study protocol. Materials & methods: A novel-design, two-phase study was applied to select a subsample of 614 children to be genotyped for the deletions of GST genes. Cumulative incidence of relapse was then estimated by weighted Kaplan–Meier analysis, and the Cox model was applied to evaluate the effect of GST-M1 and GST-T1 isoenzyme deletions on relapse. Results: No overall effect was found, but the GST-M1 deletion was associated with better clinical outcome within prednisone poor-responder patients (hazard ratio [HR]: 0.45; 95% CI: 0.23–0.91; p = 0.026), whereas the GST-T1 deletion was associated with worse outcome in the standard-risk group (HR: 4.62; 95% CI: 1.04–20.6; p = 0.045) and within prednisone good responders (HR: 1.62; 95% CI: 1.02–2.58; p = 0.041). Conclusion: Our results show that GST-M1 and GST-T1 homozygous deletions have opposite correlation with relapse, the former being protective and the latter unfavourable in specific subsets of acute lymphoblastic leukemia patients. Original submitted 1 August 2012; Revision submitted 27 September 2012
Collapse
Affiliation(s)
- Raffaella Franca
- I.R.C.C.S Burlo Garofolo, UO Pediatric Hemato-Oncology, Via dell’Istria 65/1, 34137 Trieste, Italy
| | - Paola Rebora
- Center of Biostatistics for Clinical Epidemiology, Department of Clinical Medicine & Prevention, University of Milano Bicocca, Via Cadore 48, 20052 Monza (Milano), Italy
| | - Giuseppe Basso
- Pediatric Clinic, Onco-Hematology, University of Padua, via Giustiniani 3, 35128 Padua, Italy
| | - Andrea Biondi
- Centro M Tettamanti, Clinica Pediatrica, University of Milano Bicocca, Via Pergolesi 33, 20052 Monza (Milano), Italy
| | - Giovanni Cazzaniga
- Centro M Tettamanti, Clinica Pediatrica, University of Milano Bicocca, Via Pergolesi 33, 20052 Monza (Milano), Italy
| | - Sergio Crovella
- I.R.C.C.S Burlo Garofolo, Medical Genetic Service, Via dell’Istria 65/1, 34137 Trieste, Italy
| | - Giuliana Decorti
- Department of Life Sciences, University of Trieste, Via Fleming 22, Trieste, Italy
| | - Franca Fagioli
- Pediatric Onco-Hematology, Stem Cell Transplantation & Cellular Therapy Division, Regina Margherita Children’s Hospital, Turin, Italy
| | - Emanuela Giarin
- Pediatric Clinic, Onco-Hematology, University of Padua, via Giustiniani 3, 35128 Padua, Italy
| | - Franco Locatelli
- Department of Pediatric Hematology/Oncology, I.R.C.C.S. Ospedale Pediatrico Bambino Gesù, Rome, University of Pavia, Italy
| | - Vincenzo Poggi
- Department of Pediatric Oncology, Pausilipon Hospital, via Posillipo 226, 80123 Naples, Italy
| | - Maria Grazia Valsecchi
- Center of Biostatistics for Clinical Epidemiology, Department of Clinical Medicine & Prevention, University of Milano Bicocca, Via Cadore 48, 20052 Monza (Milano), Italy
| | - Marco Rabusin
- I.R.C.C.S Burlo Garofolo, UO Pediatric Hemato-Oncology, Via dell’Istria 65/1, 34137 Trieste, Italy
| |
Collapse
|
7
|
Pigazzi M, Manara E, Bresolin S, Tregnago C, Beghin A, Baron E, Giarin E, Cho EC, Masetti R, Rao DS, Sakamoto KM, Basso G. MicroRNA-34b promoter hypermethylation induces CREB overexpression and contributes to myeloid transformation. Haematologica 2012; 98:602-10. [PMID: 23100280 DOI: 10.3324/haematol.2012.070664] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
MicroRNA-34b down-regulation in acute myeloid leukemia was previously shown to induce CREB overexpression, thereby causing leukemia proliferation in vitro and in vivo. The role of microRNA-34b and CREB in patients with myeloid malignancies has never been evaluated. We examined microRNA-34b expression and the methylation status of its promoter in cells from patients diagnosed with myeloid malignancies. We used gene expression profiling to identify signatures of myeloid transformation. We established that microRNA-34b has suppressor ability and that CREB has oncogenic potential in primary bone marrow cell cultures and in vivo. MicroRNA-34b was found to be up-regulated in pediatric patients with juvenile myelomonocytic leukemia (n=17) and myelodysplastic syndromes (n=28), but was down-regulated in acute myeloid leukemia patients at diagnosis (n=112). Our results showed that hypermethylation of the microRNA-34b promoter occurred in 66% of cases of acute myeloid leukemia explaining the low microRNA-34b levels and CREB overexpression, whereas preleukemic myelodysplastic syndromes and juvenile myelomonocytic leukemia were not associated with hypermethylation or CREB overexpression. In paired samples taken from the same patients when they had myelodysplastic syndrome and again during the subsequent acute myeloid leukemia, we confirmed microRNA-34b promoter hypermethylation at leukemia onset, with 103 CREB target genes differentially expressed between the two disease stages. This subset of CREB targets was confirmed to associate with high-risk myelodysplastic syndromes in a separate cohort of patients (n=20). Seventy-eight of these 103 CREB targets were also differentially expressed between healthy samples (n=11) and de novo acute myeloid leukemia (n=72). Further, low microRNA-34b and high CREB expression levels induced aberrant myelopoiesis through CREB-dependent pathways in vitro and in vivo. In conclusion, we suggest that microRNA-34b controls CREB expression and contributes to myeloid transformation from both healthy bone marrow and myelodysplastic syndromes. We identified a subset of CREB target genes that represents a novel transcriptional network that may control myeloid transformation.
Collapse
Affiliation(s)
- Martina Pigazzi
- Women and Child Health Department, Hematology-Oncology Laboratory, University of Padova, Padova, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Canzonetta C, Hoischen A, Giarin E, Basso G, Veltman JA, Nacheva E, Nizetic D, Groet J. Amplified segment in the 'Down syndrome critical region' on HSA21 shared between Down syndrome and euploid AML-M0 excludes RUNX1, ERG and ETS2. Br J Haematol 2012; 157:197-200. [PMID: 22221250 DOI: 10.1111/j.1365-2141.2011.08985.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Children with Down syndrome have a 20- to 50-fold increased risk of acute lymphocytic or myeloid leukaemia. Whole or partial gains of chromosome 21 have been described in multiple childhood leukaemias, and have recently been reported as a likely primary event in B-precursor-acute lymphoblastic leukaemia. It is unclear which amplified gene(s) on chromosome 21 play a key role in leukaemia progression. We describe a minimal amplified segment within the so-called 'Down syndrome critical region' shared between two cases of AML-M0; a Down syndrome, and a constitutionally normal individual. Interestingly, the amplified region does not include the oncogenes RUNX1, ETS2 and ERG.
Collapse
Affiliation(s)
- Claudia Canzonetta
- Centre for Paediatrics, Blizard Institute, Barts and The London Medical School, Queen Mary University of London, London, UK
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Buldini B, Zangrando A, Michielotto B, Veltroni M, Giarin E, Tosato F, Cazzaniga G, Biondi A, Basso G. Identification of immunophenotypic signatures by clustering analysis in pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol 2010; 85:138-41. [PMID: 20095033 DOI: 10.1002/ajh.21595] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
10
|
Santoro A, Bica MG, Dagnino L, Agueli C, Salemi D, Cannella S, Veltroni M, Cetica V, Giarin E, Fabbiano F, Basso G, Arico M. Altered mRNA expression of PAX5 is a common event in acute lymphoblastic leukaemia. Br J Haematol 2009; 146:686-9. [PMID: 19604238 DOI: 10.1111/j.1365-2141.2009.07815.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
11
|
Campo Dell'Orto M, Banelli B, Giarin E, Accordi B, Trentin L, Romani M, te Kronnie G, Basso G. Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation. Oncol Rep 2007; 18:417-23. [PMID: 17611665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023] Open
Abstract
Hypermethylation of CpG islands is the most well defined epigenetic change in neoplasia and plays an important role in the inactivation or silencing of cancer related genes. DLX genes (1-7), with large CpG islands in their 5' region, are implicated in a number of processes among which haematopoiesis. They are characterized by highly dynamic spatio-temporal expression and supposed to be involved in resistance to apoptosis of several tumor cell lines. In acute lymphoblastic leukemia (ALL) hypermethylation is a common phenomenon frequently associated with poor prognosis in specific genetic childhood leukemia subgroups. These data together with the presence of large CpG islands in the up-stream regions of the DLX genes make them attractive candidates for methylation regulated gene expression and leukemia related aberrancies. To validate the role of DLX genes in paediatric B-ALL cells, we studied two cell lines and two groups of patients with paediatric chromosomal rearrangements: MLL-AF4 and TEL-AML1, respectively. Analysis of methylation and gene expression patterns of DLX3 in 64 specimens of B-lineage ALL revealed that DLX3 presents aberrant methylation in paediatric B-ALL patients. In vitro experiments with 5-Aza-2'dC on leukemia cell lines, confirmed by Western blot analysis, indicated that the methylation of DLX3 CpG islands has a functional role and interferes with the DLX3 gene and DLX3 protein expression in B-ALL cells. Importantly, hypermethylation of DLX3 significantly reduces its expression in MLL-AF4 rearranged leukemias while methylation is almost absent in TEL-AML1 positive ALL specimens. These results show that differential DLX3 methylation could be a new epigenetic marker for genotypic B-cell leukemia subgroup with high-risk features.
Collapse
|
12
|
Campo Dell'Orto M, Banelli B, Giarin E, Accordi B, Trentin L, Romani M, Te Kronnie G, Basso G. Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation. Oncol Rep 2007. [DOI: 10.3892/or.18.2.417] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
13
|
Germano G, del Giudice L, Lo Nigro L, Polato K, Giarin E, Paganin M, Basso G. Comparative sequence analysis of incomplete DJH and TCR gene rearrangements in children with relapses of T-ALL. Leukemia 2005; 19:1687-9. [PMID: 16015384 DOI: 10.1038/sj.leu.2403878] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
14
|
Cazzaniga G, Dell'Oro MG, Mecucci C, Giarin E, Masetti R, Rossi V, Locatelli F, Martelli MF, Basso G, Pession A, Biondi A, Falini B. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005; 106:1419-22. [PMID: 15870172 DOI: 10.1182/blood-2005-03-0899] [Citation(s) in RCA: 112] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
AbstractNucleophosmin (NPM) is a nucleocytoplasmic shuttling protein involved in leukemia-associated chromosomal translocations, and it regulates the alternate reading frame (ARF)-p53 tumorsuppressor pathway. Recently, it has been demonstrated that mutations of the NPM1 gene alter the protein at its C-terminal, causing its cytoplasmic localization. Cytoplasmic NPM was detected in 35% of adult patients with primary non-French-American-British (FAB) classification M3 acute myeloid leukemia (AML), associated mainly with normal karyotype. We evaluated the prevalence of the NPM1 gene mutation in non-M3 childhood AML patients enrolled in the ongoing Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP-AML02) protocol in Italy. NPM1 mutations were found in 7 (6.5%) of 107 successfully analyzed patients. NPM1- mutated patients carried a normal karyotype (7/26, 27.1%) and were older in age. Thus, the NPM1 mutation is a frequent abnormality in AML patients without known genetic marker; the mutation may represent a new target to monitor minimal residual disease in AML and a potential candidate for alternative and targeted treatments. (Blood. 2005;106:1419-1422)
Collapse
Affiliation(s)
- Giovanni Cazzaniga
- Centro Ricerca Tettamanti, Clinica Pediatrica University of Milano-Bicocca, Ospedale San Gerardo, 20052 Monza, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Tartaglia M, Martinelli S, Iavarone I, Cazzaniga G, Spinelli M, Giarin E, Petrangeli V, Carta C, Masetti R, Aricò M, Locatelli F, Basso G, Sorcini M, Pession A, Biondi A. Somatic PTPN11 mutations in childhood acute myeloid leukaemia. Br J Haematol 2005; 129:333-9. [PMID: 15842656 DOI: 10.1111/j.1365-2141.2005.05457.x] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Somatic mutations in PTPN11, the gene encoding the transducer SHP-2, have emerged as a novel class of lesions that upregulate RAS signalling and contribute to leukaemogenesis. In a recent study of 69 children and adolescents with de novo acute myeloid leukaemia (AML), we documented a non-random distribution of PTPN11 mutations among French-American-British (FAB) subtypes. Lesions were restricted to FAB-M5 cases, where they were relatively common (four of 12 cases). Here, we report on the results of a molecular screening performed on 181 additional unselected patients, enrolled in participating institutions of the Associazione Italiana Ematologia Oncologia Pediatrica-AML Study Group, to provide a more accurate picture of the prevalence, spectrum and distribution of PTPN11 mutations in childhood AML and to investigate their clinical relevance. We concluded that PTPN11 defects do not represent a frequent event in this heterogeneous group of malignancies (4.4%), although they recur in a considerable percentage of patients with FAB-M5 (18%). PTPN11 lesions rarely occur in other subtypes. Within the FAB-M5 group no clear association of PTPN11 mutations with any clinical variable was evident. Nearly two third of the patients with this subtype were found to harbour an activating mutation in PTPN11, NRAS, KRAS2 or FLT3.
Collapse
Affiliation(s)
- Marco Tartaglia
- Dipartimento di Biologia cellulare e Neuroscienze, Istituto Superiore di Sanità, 299-00161 Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Germano G, del Giudice L, Palatron S, Giarin E, Cazzaniga G, Biondi A, Basso G. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring. Leukemia 2003; 17:1573-82. [PMID: 12886245 DOI: 10.1038/sj.leu.2403008] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Detection of minimal residual disease (MRD), using immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements as clone-specific targets, represents the most recent development in diagnosis and treatment of acute lymphoblastic leukaemia (ALL). Nevertheless, risk of false-negative results, due to secondary or ongoing rearrangements of Ig/TCR genes during the disease course, might hamper MRD detection. Therefore, to gain extensive information on clonal stability, we performed PCR-GeneScan analysis of Ig/TCR gene rearrangements at diagnosis and subsequent relapse in bone marrow samples from 53 childhood precursor-B-ALL patients. In addition, sequencing analysis of junctional regions at diagnosis and relapse provided a detailed insight in the stability and changes of Ig/TCR gene rearrangements during the disease course. At least one stable clonal Ig/TCR target was found in 94% of patients. In three patients complete differences in Ig/TCR rearrangements between diagnosis and relapse were observed, suggesting relapse with a new clone. At relapse, 71% of diagnostic clonal PCR targets was conserved. Since the comparison of Ig/TCR gene rearrangements at diagnosis and relapse in our precursor-B-ALL patients did not show significant difference in the stability of different clonal PCR targets (IGH, 70%; IGK, 71%; TCRD, 67%; TCRG, 75%), we conclude that there is no 'preferential' clone-specific target for MRD monitoring.
Collapse
Affiliation(s)
- G Germano
- Laboratorio di Emato Oncologia, Dipartimento di Pediatria, Universita' di Padova, Italy
| | | | | | | | | | | | | |
Collapse
|